Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ESMO 2020

18 - 22 Sep 2020

Online, Global

ESMO 2020: New developments in the treatment of lung cancer

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

ESMO 2020: New developments in the treatment of lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

SAFIR 02: Durvalumab compared to maintenance chemotherapy for metastatic non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

PIONeeR: Understanding PD-L1 resistances in non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

Sotorasib for advanced non-small cell lung cancer

Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France

Sotorasib for advanced non-small cell lung cancer ( Prof Fabrice Barlesi - Gustave Roussy, Villejuif, France )

OS results from SOLAR-1: Alpelisib plus fulvestrant for HR positive, HER2 negative advanced breast cancer

Prof Fabrice André - Institut Gustave Roussy, Paris, France

OS results from SOLAR-1: Alpelisib plus fulvestrant for HR positive, HER2 negative advanced breast cancer ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )

ESMO 2020 melanoma roundup

Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany

ESMO 2020 melanoma roundup ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )

Nivolumab for oesophageal cancer following chemoradiation therapy

Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA

Nivolumab for oesophageal cancer following chemoradiation therapy ( Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA )

PROFound trial and other recent updates in prostate cancer

Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain

PROFound trial and other recent updates in prostate cancer ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

ESMO 2020 renal roundup

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ESMO 2020 renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Exon 20 insertions in NSCLC - ESMO 2020

Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro

Exon 20 insertions in NSCLC - ESMO 2020 ( Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro )

ESMO 2020: Lung cancer latest

Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Popat

ESMO 2020: Lung cancer latest ( Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Popat )

Highlights from ESMO 2020

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Highlights from ESMO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

PARP inhibitors and their evolving role for the treatment of prostate cancer

Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi

PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )

KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer

Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan

KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer ( Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan )

Disparities in access to oncology clinical trials across Europe

Prof Ana Carneiro - Lund University, Lund, Sweden

Disparities in access to oncology clinical trials across Europe ( Prof Ana Carneiro - Lund University, Lund, Sweden )

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC

Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC ( Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA )

ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

Breast cancer roundup from ESMO 2020

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ESMO 2020 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer

Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA

IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer ( Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA )

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer

Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan

ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer ( Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan )

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection

Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan

Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers

Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany

CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )

Estimate of the 2-year oncology workload generated by each new patient: A real-world study

Dr Silvio Ken Garattini - University of Udine, Udine, Italy

Estimate of the 2-year oncology workload generated by each new patient: A real-world study ( Dr Silvio Ken Garattini - University of Udine, Udine, Italy )

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC

Dr Alex Spira and Dr Joshua Sabari

Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )

Impact of COVID-19 pandemic on cancer care: A global collaborative study

Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia

Impact of COVID-19 pandemic on cancer care: A global collaborative study ( Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia )

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer

Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )

LungART: Radiotherapy after surgery for patients with non small cell lung cancer

Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France

LungART: Radiotherapy after surgery for patients with non small cell lung cancer ( Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France )

Personalised molecularly matched therapies for carcinomas of unknown primary

Dr Jacob Adashek - University of South Florida, Tampa, USA

Personalised molecularly matched therapies for carcinomas of unknown primary ( Dr Jacob Adashek - University of South Florida, Tampa, USA )

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Impact of COVID-19 on oncology professionals

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Impact of COVID-19 on oncology professionals ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC

Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France

Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC ( Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France )

More from ecancer